Highlights

  • The Calmer Co has entered a strategic partnership framework with Kaiming Agro Processing to expand botanical manufacturing capability.
  • The partnership supports production of kava, ginger and turmeric extracts, subject to definitive agreements.
  • KAPPL’s advanced Fiji manufacturing facility is expected to include supercritical CO₂ extraction capability.
  • The Calmer Co shares traded flat at AUD 0.0020 during morning session on 30 July 2026.

The Calmer Co International Limited (ASX:CCO) announced a strategic manufacturing partnership with Kaiming Agro Processing Pte Ltd’s subsidiary Pacific Culture and Heritage Pte Ltd, establishing a framework to expand production capability across kava, ginger and turmeric botanical extracts.

The company’s shares traded flat at AUD 0.0020 during the morning session on 30 July 2026 as investors assessed the latest strategic update. The announcement follows The Calmer Co’s ongoing efforts to expand its premium botanical ingredients platform and branded consumer products portfolio.

The Binding Strategic Partnership Heads of Agreement (HOA) with KAPPL is intended to combine advanced manufacturing capability with The Calmer Co.’s existing strengths in premium raw material sourcing, proprietary formulations, internationally recognised brands and global commercialisation.

Strategic Partnership Creates New Manufacturing Pathway

The Calmer Co stated that the agreement establishes the framework for negotiating definitive agreements for a long-term strategic manufacturing partnership.

Under the proposed structure, KAPPL is expected to become the preferred manufacturing partner for agreed Fiji-manufactured products, subject to the completion of definitive agreements.

The partnership is designed to support The Calmer Co.’s strategy of expanding its premium botanical ingredients business while continuing to develop its branded consumer products portfolio.

The company will continue maintaining control over key areas including premium raw material procurement, proprietary formulations, product specifications, intellectual property, Fiji Kava®, Taki Mai® and Authentic Kava® brands, customer relationships and global commercialisation activities.

KAPPL will provide advanced manufacturing capabilities for agreed products and botanical ingredients, creating a model that combines The Calmer Co.’s commercial platform with KAPPL’s processing expertise.

The company stated that the partnership is intended to provide additional manufacturing capability while maintaining existing relationships with specialist extraction partners in Australia and India.

Fiji Manufacturing Facility Expected to Expand Production Capability

A major component of the partnership is KAPPL’s investment in a new advanced botanical manufacturing facility in Navua, Fiji.

The facility is currently under construction and is expected to incorporate supercritical CO₂ extraction technology along with expanded processing infrastructure.

Commissioning of the facility is expected in December 2026.

The Calmer Co stated that the facility is expected to increase Fiji’s capability in producing premium botanical ingredients and value-added consumer products for international markets.

The additional manufacturing capability is expected to complement the company’s existing specialist extraction partners while providing greater production flexibility.

According to The Calmer Co, the partnership may support several operational benefits, including expanded manufacturing capacity, improved supply chain flexibility, continued product innovation and increased value-added botanical processing within Fiji.

The company intends to progressively integrate KAPPL’s manufacturing capabilities into its broader manufacturing network as commercial opportunities develop.

Partnership Supports Growing Botanical Ingredients Platform

The partnership has been established as both companies continue expanding their respective capabilities in the botanical products sector.

KAPPL has developed experience as a producer and exporter of value-added botanical products, supplying customers across Australia, New Zealand, North America, the United Kingdom and Europe.

The company has invested in advanced processing infrastructure aimed at increasing its manufacturing capability for premium botanical ingredients.

The Calmer Co has spent several years developing its own commercial platform through investment in research and development, proprietary formulations, supply chains, extraction technologies, regulatory capabilities and international customer relationships.

The company stated that these investments have created commercial opportunities across ingredient supply, branded consumer products and international partnerships.

By combining these capabilities, The Calmer Co believes the partnership provides a scalable operating model that allows each organisation to focus on its respective strengths.

Kava, Ginger and Turmeric Markets Remain Key Growth Areas

The Calmer Co highlighted continued global interest in value-added botanical extracts across categories relevant to the partnership.

The company referenced external market research indicating continued expansion in turmeric, ginger extract and kava root extract markets.

Future Market Insights estimates the global turmeric market could increase from approximately US$4.9 billion in 2025 to US$8.4 billion by 2035, representing a compound annual growth rate of 5.5%.

Market Research Future estimates the global ginger extract market could grow from approximately US$1.36 billion in 2025 to US$2.30 billion by 2035, representing a compound annual growth rate of 5.4%.

Fortune Business Insights estimates the global kava root extract market could increase from approximately US$1.87 billion in 2025 to US$7.40 billion by 2034, representing a compound annual growth rate of 16.58%.

The company noted that these market research figures are sourced from independent third-party reports and do not represent company forecasts or guarantees.

The Calmer Co Retains Control of Brands and Commercial Activities

A key element of the partnership structure is that The Calmer Co will continue controlling its core commercial assets.

The company will retain ownership of its premium raw material supply arrangements, proprietary formulations, intellectual property and internationally recognised brands.

The partnership allows KAPPL to focus on manufacturing activities, transforming company-supplied raw materials into premium botanical ingredients and finished branded consumer products according to The Calmer Co.’s specifications and quality requirements.

The company believes this structure creates a capital-efficient approach by leveraging KAPPL’s manufacturing investment while allowing The Calmer Co to focus resources on innovation, brand development and international expansion.

Three-Phase Partnership Roadmap Outlined

The Heads of Agreement establishes a three-phase framework for potential collaboration between The Calmer Co and KAPPL.

The first phase focuses on establishing the manufacturing relationship and transitioning agreed production activities to KAPPL’s new facility, subject to definitive agreements.

Key activities may include relocating agreed manufacturing equipment, establishing equipment lease arrangements, manufacturing Fiji Kava®, Taki Mai® and Authentic Kava® branded products, producing premium botanical ingredients and implementing quality assurance systems.

The second phase provides a framework to evaluate potential manufacturing asset transition and further expansion of production capability.

This phase may include additional manufacturing capacity, operational optimisation and further investment in botanical processing infrastructure.

The third phase allows both parties to evaluate broader strategic integration opportunities, which may include equity participation, joint venture structures, contribution of manufacturing assets or other agreed arrangements.

Progression beyond the initial phase is not automatic and remains subject to future agreements, approvals and commercial milestones.

The Calmer Co Focuses on Scalable Growth Model

The company stated that the partnership provides a pathway to strengthen its premium botanical ingredients platform without requiring substantial additional manufacturing investment.

By leveraging KAPPL’s planned advanced processing capability, The Calmer Co aims to continue focusing on areas where it has established expertise, including sourcing, innovation, product development, brand building and global commercialisation.

The company also believes the partnership could contribute to Fiji’s position as a producer of premium value-added botanical products by increasing local processing capability.

About The Calmer Co

The Calmer Co International Limited is a consumer packaged goods company specialising in kava and other natural products designed to support relaxation and sleep.

The company distributes products globally through e-commerce channels and retail partnerships, supported by a farm-to-shelf supply chain.

Its product portfolio includes drinking powders, natural and flavoured kava shots, concentrates and capsules.

The company’s brands include Fiji Kava®, Taki Mai® and Danodan Hempworks, with products available across markets including the United States, Australia, New Zealand, China and the Pacific Islands.

What This Means for Investors?

The Calmer Co’s latest announcement highlights a strategic move aimed at expanding manufacturing capability while supporting the company’s broader botanical ingredients and consumer products strategy.

The partnership with KAPPL introduces a potential pathway for additional production capacity in Fiji while allowing The Calmer Co to retain control over its brands, intellectual property and commercial relationships.

Investors are likely to monitor the progression of definitive agreements, commissioning of KAPPL’s manufacturing facility and the company’s ability to convert expanded production capability into future commercial opportunities.